Tetratherix CEO Will Knox talks IPO, Tetramatrix, and upcoming milestones

Tetratherix Limited CEO Will Knox talked with Proactive's Stephen Gunnion about the company’s transformation from an R&D-focused operation to a commercial-stage biomedical business. The company recently completed a successful IPO, raising A$25 million to fund the development of a new manufacturing facility. This marks a significant step in enabling commercial-scale production of its platform biomaterial technology, Tetramatrix. Knox explained that Tetratherix is focusing on five specific products across three key clinical franchises: bone regeneration, tissue spacing, and scar prevention. He highlighted applications in oral, facial, and orthopaedic procedures, as well as prostate cancer therapy and cataract surgery. The company’s TetraDerm product also targets the surgical scarring market. A core differentiator of Tetramatrix is its synthetic, injectable form that transforms into a gum-like consistency at body temperature. According to Knox, "There is a very minimal inflammatory response to the product itself, which means that the body essentially doesn't recognise that it's there.” FDA approval is expected in the first half of 2026, with initial US launches planned before broader international expansion. Knox noted that investors can expect “a constant stream of news” over the next 12 to 18 months, including clinical and commercial updates across all five product areas. For more interviews and updates, visit Proactive's YouTube channel. Don't forget to give this video a like, subscribe to the channel, and enable notifications for future content. #Tetratherix #WillKnox #BiotechStocks #FDAApproval #MedicalInnovation #BoneRegeneration #IPO2025 #Tetramatrix #ScarPrevention #TissueSpacing #BiomedicalTechnology #HealthcareInvesting